Long-term follow-up of kidney transplant recipients admitted to a tertiary care transplant center with SARS-CoV-2

Table 5 Risk for coronavirus disease 2019-related mortality

Covariate	Univariate analyses			Multivariate analyses
	HR	95%CI	P value	HR	95%CI	P value
ICU admission	25.5	8.26-78.8	< 0.001	27.2	8.69-84.9	< 0.001
Age at SARS-CoV-2 infection diagnosis (per year)	1.04	0.99-1.07	0.06	1.04	1.0-1.08	0.04
Male recipient	1.75	0.66-4.59	0.26
Nonwhite recipient	0.54	0.16-1.85	0.33
Diabetes as a cause of ESKD vs other	0.66	0.22-1.99	0.46
Living donor recipient	0.68	0.25-1.90	0.47
Previous transplant	0.48	0.14-1.66	0.25
Tacrolimus + MPA + prednisone maintenance vs other	1.33	0.44-4.02	0.61
Prednisone based immunosuppression	0.52	0.15-1.77	0.30
Treatment of rejection before SARS-CoV-2 infection	--	--	--
Vaccinated	0.66	0.26-1.60	0.35
Baseline eGFR (per mL/m2)	1.01	0.99-1.03	0.27
Interval from transplant to SARS-CoV-2 infection (per month)	1.0	0.99-1.01	0.68
Respiratory symptoms for hospital admission	1.13	0.43-2.99	0.80
Remdesivir for management of COVID	0.62	0.21-1.88	0.40

COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; eGFR: Estimated glomerular filtration rate; ICU: Intensive care unit; ESKD: End-stage kidney disease; MPA: Mycophenolic acid.